Autolus Therapeutics plc
NASDAQ:AUTLBiotechnology
+$0.01 today
- Market cap
- $282.13M
- Beta
- 2.01
- P/E (TTM)
- -1.4
- EPS (TTM)
- -$1.09
Volume 2.56M
Average 1.60M
AUTL Revenue
Total income from selling goods and services before any costs are deducted; the top line of the income statement.
Autolus Therapeutics plcNASDAQ: AUTL
Revenue · Q1 FY2026 · quarter ended Mar 2026
Revenue grows, but more slowly than its trailing trend
Q1 FY2026 revenue of $26.22M rose 191.9% year over year, behind the +927.5% change in trailing-twelve-month revenue. Sequentially, it rose 8.1% from the prior quarter. Over 3 fiscal years it compounded at +130.2% a year.
Context
- Revenue increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether revenue reaches the consensus estimate from 6 analysts of $152.42M (+101.7%) for the fiscal year ending Dec 2026, a slowdown from the +646.7% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $26.22M+8.1% QoQ
- Last fiscal yearDec 2025
- $75.56M+646.7% YoY
- LTMMar 2026
- $92.59M+927.5% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +191.9% | +84.3% | -107.6 pp |
| 1 year | +646.7% | +101.7% | -545.0 pp |
| 3-year CAGR | +130.2% | +56.7% | -73.5 pp |
| 5-year CAGR | +51.0% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Revenue history
USD · from the income statement
- Latest · FY2025
- 75.56M USD
- Year-over-year change
- +646.7%
- 4-year CAGR
- +166.1%
| Period | Period end | Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 75.56M | +646.7% |
| FY2024 | 2024-12-31 | 10.12M | +496.0% |
| FY2023 | 2023-12-31 | 1.7M | -72.6% |
| FY2022 | 2022-12-31 | 6.19M | +311.0% |
| FY2021 | 2021-12-31 | 1.51M | — |
Revenue vs competitors
How AUTL compares with its peers on the latest reported figures
- AUTL's LTM Mar 2026 revenue of $92.59M is the 2nd highest of the 10 companies compared; the peer median is $11.2M.
- Its year-over-year change of +927.5% is the highest of 9, against a peer median of -32.1%.
- Over three fiscal years its annual growth of +130.2% compares with a peer median of +17.4%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Sep 2026 | $1.36B | +49.5% | +106.4% | |
| LTM Mar 2026 | $92.59M | +927.5% | +130.2% | |
| LTM Mar 2026 | $68.09M | +42.9% | +56.1% | |
| LTM Mar 2026 | $45.07M | -11.9% | +10.9% | |
| LTM Mar 2026 | $23.14M | -88.4% | +23.9% | |
| LTM Mar 2026 | $11.2M | +13.0% | -7.0% | |
| LTM Mar 2026 | $6.32M | -52.6% | -59.0% | |
| LTM Mar 2026 | $31K | -52.3% | -92.5% | |
| LTM Mar 2026 | $0 | -100.0% | +175.9% | |
| LTM Mar 2026 | $0 | — | — | |
| Peer median (excluding AUTL) | $11.2M | -32.1% | +17.4% | |
Competitors are the stored peer set for AUTL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 1.51M | 6.19M | 1.7M | 10.12M | 75.56M |
| Cost of Revenue | 0 | 0 | 0 | 141.02M | 96.59M |
| Gross Profit | 1.51M | 6.19M | 1.7M | (130.9M) | (21.03M) |
| Gross Margin | 100.0% | 100.0% | 100.0% | -1293.5% | -27.8% |
| Research & Development | 110.84M | 117.35M | 130.48M | 158.14M | 128.59M |
| Selling, General & Admin | 31.87M | 31.9M | 46.75M | 0 | 131.82M |
| Operating Expenses | 141.88M | 149.09M | 181.4M | 110.53M | 260.41M |
| Depreciation & Amortization | 8.46M | 7.42M | 6.57M | 7.72M | 9.84M |
| EBITDA | (132.48M) | (132.24M) | (156.77M) | (233.07M) | (250.26M) |
| EBITDA Margin | -8790.6% | -2135.0% | -9232.6% | -2303.1% | -331.2% |
| Operating Income | (140.37M) | (142.89M) | (179.7M) | (241.43M) | (281.44M) |
| Operating Margin | -9314.8% | -2307.0% | -10583.1% | -2385.6% | -372.4% |
| Interest Income | 262K | 1.71M | 13.51M | 32.36M | 19.02M |
| Interest Expense | 1.11M | 8.91M | 45.07M | 9.29M | 36.76M |
| Other Income / Expenses | (1.66M) | (5.67M) | (28.7M) | 22.29M | (15.41M) |
| Income Before Tax | (142.04M) | (148.57M) | (208.4M) | (219.13M) | (296.85M) |
| Pre-Tax Margin | -9425.2% | -2398.6% | -12273.4% | -2165.4% | -392.8% |
| Income Tax Expense | 58K | 272K | (19K) | 1.53M | (8.65M) |
| Net Income | (142.1M) | (148.84M) | (208.38M) | (220.66M) | (288.2M) |
| Net Margin | -9429.1% | -2403.0% | -12272.3% | -2180.5% | -381.4% |
| EPS (Basic) | (1.97) | (1.57) | (1.20) | (0.87) | (1.08) |
| EPS (Diluted) | (1.97) | (1.57) | (1.20) | (0.87) | (1.08) |
| Weighted Avg Shares | 72.08M | 94.99M | 173.94M | 255.16M | 266.14M |
| Weighted Avg Shares (Diluted) | 72.08M | 94.99M | 173.94M | 255.16M | 266.14M |
Autolus Therapeutics plc
NASDAQ:AUTL
Intrinsic Alpha fair value
Locked
Current Price
$1.06
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.